Elevance Health, Inc. (NYSE:ELV) saw Baird analyst Michael Ha reduce the price target on the company’s stock to $297 from $492, maintaining a “Neutral” rating. The firm remains cautious on Medicaid and healthcare exchange in an evolving external environment.

In Q2 2025, Elevance Health, Inc. (NYSE:ELV) reported operating revenue of $49.4 billion, a 14% increase from Q2 2024. This growth was driven by premium yield increases, recent acquisitions, and Medicare Advantage membership growth, offset by Medicaid attrition.

Hotchkis & Wiley highlighted Elevance Health, Inc. (NYSE:ELV) as an undervalued health insurer with strong business fundamentals. ELV reported stable earnings, improved Medicaid utilization trends, and projected stable Medicare Advantage margins in 2025.

Despite ELV’s potential, some AI stocks may offer greater upside with less downside risk. For those seeking an undervalued AI stock with potential benefits from current economic trends, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Baird Reduces PT on Elevance Health (ELV) Stock, Maintains Neutral